First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland
Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2025-01-01
|
| Serie: | Current Oncology |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1718-7729/32/2/64 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|